Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus Docetaxel in mCRPC
NCT04907227Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2020
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Pembrolizumab+Docetaxel with Placebo+Docetaxel (2 arms). Primary endpoints: Overall Survival up to 19.8 months and Radiographic Progression-free Survival up to 19.8 months. Started Sep 2020; status: terminated.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04907227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04907227.